Although biological drugs targeting TNF, IL-17, and IL-12/IL-23 have been approved for the treatment of psoriatic arthritis with destructive spondyloarthritis, there is no way to differentiate the use of these drugs. This evidence concerns the gene TNF and psoriatic arthritis.